Plasma steroid and luteinizing hormone levels during prostaglandin F 2   administration in luteal phase of menstrual cycle.
An intravenous infusion of prostaglandin F(2)alpha (12.5-250mug/min) was administered in four volunteers in the mid-late luteal phase and three in the early luteal phase of the menstrual cycle.Frequent measurement of plasma progesterone, oestrogens, and luteinizing hormone (LH) showed that administration of high doses depressed plasma progesterone levels in the late luteal phase and caused concomitant side effects. Levels of progesterone in the early luteal phase were unaffected. In both phases oestrogen and LH levels were little altered. In two subjects, hourly progesterone levels measured throughout the day at a similar time in a subsequent control menstrual cycle showed an appreciable variation in one but steady levels in the second. This variation may contribute to the magnitude of the fall in progesterone noted during the infusion of prostaglandins.
D000293:Adolescent; D000328:Adult; D003338:Corpus Luteum; D004967:Estrogens / Q000097:blood*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007986:Luteinizing Hormone / Q000097:blood*; D008598:Menstruation; D011374:Progesterone / Q000097:blood*; D011453:Prostaglandins / Q000494:pharmacology*; D011485:Protein Binding
D004967:Estrogens; D011453:Prostaglandins; D011374:Progesterone; D007986:Luteinizing Hormone